NCT00747617View on ClinicalTrials.gov

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

September 30, 2010

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

recombinant human chorionic gonadotropin

Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.

Trial Locations (1)

92093

University of California, San Diego, School of Medicine, La Jolla

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT00747617 - Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) | Biotech Hunter | Biotech Hunter